NeoTX is a clinical-stage immuno-oncology company advancing our Tumor Targeted Superantigen (TTS) platform. The company’s lead TTS molecule, naptumomab estafenatox (NAP), is currently in clinical development for advanced solid tumors (NCT03983954). NeoTX plans to start multiple Phase 1b and Phase 2 trials with NAP in 2021 in patient populations with high unmet medical need. One of those studies is a basket trial encompassing different tumor types that have a specific molecular signature that is known to be resistant to current immunotherapies. This trial, which is projected to complete in Q4 2022, may lead to a registrational Phase 3 trial and accelerated approval.


TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells in the periphery, away from the suppressive tumor environment, to mount an effective antibacterial response. TTS creates a natural de novo antibacterial immune response to cancer, potentially overcoming multiple resistance pathways and leading to long-term survival.

Management Team

Asher Nathan has extensive experience in diverse roles within the industry, including founder, entrepreneur and investor and has authored over 25 patents in the field of biotechnology. Before NeoTX, he founded IntelliGene and EvoRx, two biotech companies formed around technologies he invented. EvoRx was established together with Nobel Prize Winners Arthur Kornberg and Roger Kornberg.  He was a Managing director at Paramount Biocapital, a drug development and healthcare investment firm which created over 40 start-up companies, before he co-founded Zoticon Bioventures, where he served as Managing Director.

Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006. Collectively, Dr. Kornberg’s research has revolutionized modern genetics, molecular biology and the understanding of pathogenesis of various cancer malignancies. Among Dr. Kornberg’s many awards and prizes was the Alfred P. Sloan, Jr., Prize from the General Motors Cancer Research Foundation, and the Robert J. and Claire Pasarow Foundation Medical Research Award in Cancer Research.

Dr. Rozencweig is a medical oncologist with more than 40 years of experience in clinical trials and anti-cancer drug development at the National Cancer Institute and in the pharmaceutical industry. Dr. Rozencweig has served in various global drug development leadership positions at Bristol-Myers Squibb in worldwide clinical R&D, strategic marketing, portfolio management, and portfolio development. He built and led the BMS clinical research group that developed all NCE’s brought to market in the field of cancer from 1983 to 2001. Dr. Rozencweig has held senior management positions at several small US and international biotechnology companies.

Mr. Harow has completed over $2 Billion in financing and advisory work. Before co-founding NeoTX, Mr. Harow co-founded Zoticon Bioventures, where he served as Managing Partner. While at Zoticon, he raised over $100 Million for investment in its portfolio companies. Mr. Harow previously served as Managing Director at the Trout Group, a global investor relation and a strategic advisory company dedicated solely to the life science industry. Before Trout, he was a Senior Vice President at Gerard Klauer Mattison (now part of BMO Group), a research and investment-banking firm.

Dr. Lloyd is a leading regulatory expert with over 25 years of experience in global regulatory affairs and quality assurance. She has led or directed teams in the submission and marketing approval of over a dozen small molecule, biologic and biologic/device combination products in a wide variety of therapeutic areas such as oncology, endocrinology/metabolism, antivirals, respiratory and psychiatric disorders. Prior to joining NeoTX, Dr. Lloyd served as a consultant to the pharmaceutical industry and as a senior executive with Sanofi-Aventis, Bristol Myers-Squibb, and Johnson and Johnson. She acted as Sr. Vice President of Global Regulatory Affairs and Drug Safety at ImClone Systems Inc., a wholly-owned subsidiary of Eli Lilly and has served as Vice President, Worldwide Regulatory Affairs and Quality for both public and private biotechs such as GPC Biotech Inc. and Omthera.

Dr. Lloyd earned her professional credentials in regulation of healthcare products, Regulatory Affairs Certified (RAC), and has distinguished herself as a scientist with numerous awards and publications. She holds a doctorate in Molecular Genetics and Microbiology from Rutgers University – Robert Wood Johnson Medical School and was a researcher at the Center for Advanced Biotechnology and Medicine. She was recognized by the Biomedical Engineering Department of Rutgers University with the 2003 Distinguished Alumni Award and served as a member of the Industrial Advisory Board, Department of Biomedical Engineering.

Dr. Shahar has extensive experience in leading research and development programs in oncology and immune-oncology. Before joining NeoTX, she served as VP of Research and Development at Efranat Ltd, an immuno-oncology drug development company. Previously, she served as Director of Project Management for TransPharma Medical, where she led the development of their main product in collaboration with Eli Lilly. Dr. Shahar has also served as Director of R&D of the Pharma and Cosmetics division of Power Paper Ltd, Head of the Pre-clinical lab at Zetiq Technologies Ltd, and Senior Scientist and Project Leader at Prof. Yechiel Shai lab at Weizmann Institute of Science. Dr. Shahar holds a PhD in Biochemistry from the Bar-Ilan University, Israel.

Board of Directors

Mr. Marinelli has served as President of Lawrence Investments, LLC, a private equity investment firm that is controlled by Lawrence J. Ellison, since 2015 (and as Vice President from 2004-2015). From 1999 to 2004, he held the position of Corporate Development Group Director at Cadence Design Systems, an electronic design automation software and services company, where he managed several dozen acquisitions and strategic investments. Prior to 1999, Mr. Marinelli held various financial roles at PricewaterhouseCoopers, a global professional services firm, AlliedSignal, an aerospace, automotive and engineering company, and EMCON, an environmental engineering firm. Mr. Marinelli earned a B.S. from the University of California, Berkeley, and an M.B.A. from Cornell University. Mr. Marinelli has served as an officer and/or director of several companies owned by Mr. Ellison, including LeapFrog Enterprises (NYSE: LF), Hawaii Island Air, Tennis Ventures, LLC (owner of the BNP Paribas tennis tournament in Indian Wells, California) and Lanai Resorts, LLC (owner of the Hawaiian island of Lanai).

Mr. Hill is a private investor, whose career has spanned both the investment banking and the asset management business since 1973. Prior to January 2019, Mr. Hill was the President and CEO of Blackstone Alternative Asset Management and Vice Chairman of Blackstone Group where he served as a member of the Board of Directors of Blackstone’s general partner since March 2007. Mr. Hill is a graduate of Harvard College and the Harvard Business School. He is a member of the Council on Foreign Relations where he is Chairman Emeritus of the Investment Committee and serves on the Council’s Investment Committee and is a member of the Board of Directors of Lincoln Center Theater, where he is Chairman Emeritus. He is Chairman Emeritus of the Hirshhorn Museum and Sculpture Garden in Washington, D.C., and currently serves on the Investment Committee of the Smithsonian Institution and the Executive Committee and the Board of Trustees of The Metropolitan Museum of Art. He also serves on the Board of the Guggenheim Museum, the Telluride Foundation, the Advantage Testing Foundation, the Friends of the High Line, and Our Lady Queen of Angels School, a parochial school (K-8th grade) in Spanish Harlem. He is a member of the Advisory Board of Christie’s and a member of the Board of Directors of First Eagle Investment Management, Hamilton Insurance Group, Limited, Advantage Testing, Inc. and Crux Informatics.

Florence A. Davis has served as President and a member of the Board of Directors of The Starr Foundation since March 1999. A graduate of Wellesley College (highest honors, Phi Beta Kappa) and New York University School of Law (Root-Tilden Scholar), she began her legal career in private practice with Sullivan & Cromwell in 1979. From 1986-1995, Ms. Davis served in a number of positions at Morgan Stanley & Co., Incorporated, where she rose to become a Principal and Director of Worldwide Regulatory Affairs. From 1995-1999, Ms. Davis was Vice President and General Counsel of American International Group, Inc. (“AIG”). She is retired from the practice of law.

Ms. Davis is a trustee of the New York University School of Law and serves as Vice Chairman of the board, and a member of the Board of Trustees of the New York Botanical Garden, where she serves as Chairman of the Audit Committee of the board. She is a member of the Council on Foreign Relations, the advisory board of the Newman’s Own Foundation, and the Dean’s Advisory Council at Weill Cornell Medicine.

Mr. Kim has over 15 years of professional experience managing private equity funds. During his career, he has executed $400 million in M&A transactions. Mr. Kim is founder & CEO of Riverstone Investment Co., Ltd., which was formed in 2010, and Chairman of NDFOS (KOSDAQ:238090). He currently serves as a member of the Board of Directors of Immunomet Therapeutics and Zyversa Therapeutics. Mr. Kim was formerly Co-founder & CIO at Liberty Investment Co., Ltd. He received a BA in economics from Cornell University.